Genetic evidence of XBP1 in AF and breast cancer provides new ideas for the treatment of both, but a large number of studies are still needed to validate the feasibility and safety of drug-targeted inhibition of XBP1 in the combined state of the two diseases. This evidence concerns the gene XBP1 and atrial fibrillation.